These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29277796)

  • 41. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
    Jørgensen JT
    World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.
    Ilhan-Mutlu A; Taghizadeh H; Beer A; Dolak W; Ba-Ssalamah A; Schoppmann SF; Hejna M; Birner P; Preusser M
    Cancer Biol Ther; 2018 Mar; 19(3):169-174. PubMed ID: 29252101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
    Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
    Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
    Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
    J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
    Boers JE; Meeuwissen H; Methorst N
    Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    Müller V; Clemens M; Jassem J; Al-Sakaff N; Auclair P; Nüesch E; Holloway D; Shing M; Bang YJ
    BMC Cancer; 2018 Mar; 18(1):295. PubMed ID: 29544445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
    Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
    J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
    Grávalos C; Gómez-Martín C; Rivera F; Alés I; Queralt B; Márquez A; Jiménez U; Alonso V; García-Carbonero R; Sastre J; Colomer R; Cortés-Funes H; Jimeno A
    Clin Transl Oncol; 2011 Mar; 13(3):179-84. PubMed ID: 21421462
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
    Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
    Shah MA; Kang YK; Thuss-Patience PC; Ohtsu A; Ajani JA; Van Cutsem E; Hoersch S; Harle-Yge ML; de Haas SL
    Gastric Cancer; 2019 Jul; 22(4):803-816. PubMed ID: 30706247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
    Kumarasinghe MP; Morey A; Bilous M; Farshid G; Francis G; Lampe G; McCue G; Von Neumann-Cosel V; Fox SB
    Pathology; 2017 Oct; 49(6):575-581. PubMed ID: 28823752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
    Bouché O; Penault-Llorca F
    Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
    Pietrantonio F; Caporale M; Morano F; Scartozzi M; Gloghini A; De Vita F; Giommoni E; Fornaro L; Aprile G; Melisi D; Berenato R; Mennitto A; Volpi CC; Laterza MM; Pusceddu V; Antonuzzo L; Vasile E; Ongaro E; Simionato F; de Braud F; Torri V; Di Bartolomeo M
    Int J Cancer; 2016 Dec; 139(12):2859-2864. PubMed ID: 27578417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811.
    Yu J; Saeed A
    Chin Clin Oncol; 2024 Aug; 13(4):59. PubMed ID: 38859610
    [No Abstract]   [Full Text] [Related]  

  • 57. HER2 testing in gastric and gastroesophageal adenocarcinomas.
    Vakiani E
    Adv Anat Pathol; 2015 May; 22(3):194-201. PubMed ID: 25844677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
    Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.